Lewisville, Texas, May 23, 2024–(BUSINESS WIRE)–Orthofix Medical, Inc. (NASDAQ:OFIX), a leading global spine and orthopedic company, today announced the appointment of Max Reinhardt as president of its global spine business, effective June 10, 2024. Announced. Executive Leadership He will be part of the team and will be responsible for leading SeaSpine, our global spine and biologics business.
Mr. Reinhardt has more than 30 years of experience in the medical technology and pharmaceutical industries and served as Worldwide President of DePuy Synthes Spine at Johnson & Johnson, where he achieved No. 2 market share in the highly competitive spine market. He has held a number of positions of responsibility, including: He further served as Vice President of Orthopedic Marketing, Joint Reconstruction, Sports Medicine, and Power Tools Global Franchise Leader and Worldwide President. Mr. Reinhardt works closely with his key opinion leaders to launch his market-leading biologics and implant solutions in the areas of spine surgery, joint replacement, orthopedic trauma, and early intervention, technology-based and robust. supported by a specialized training program.
“Max brings strong leadership and a proven track record to our global spine business,” said Massimo Calafiore, Orthofix president and CEO. “He has extensive experience driving innovation and continually executing focused strategies to drive commercial success. We look forward to the guidance and expertise he will bring to the company as we continue to accelerate and position Orthofix as one of the leading spine companies in the market.”
Prior to joining Johnson & Johnson, Mr. Reinhardt held senior management positions at Steris and Olympus in Europe. Most recently, he held various management positions at Pacira Biosciences, a company focused on providing innovative non-opioid pain relief solutions.
“I am pleased to have the opportunity to lead OrthoFix's talented spine team as we continue to innovate and bring to market differentiated products and procedurally integrated solutions to solve complex spine problems,” said Reinhardt. “I believe the company has a strong foundation and is well positioned for growth over the next few years. I look forward to working with our dedicated team members to deliver new product solutions and provide excellent support to our surgeon customers and their patients.”
Reinhardt holds a BA from Sparsholt College, Hampshire, UK, and an MSc from Hull University, UK.
About Orthofix
Orthofix is one of the world's leading spine and orthopedic companies with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and state-of-the-art surgical navigation systems. The company's products are sold in more than 60 countries around the world.
The company is headquartered in Lewisville, Texas, with general operations, product development, medical education and manufacturing operations, and has a principal office in Carlsbad, California, with a focus on spine and biologics product innovation and surgeon education. I am putting It is also based in Verona, Italy. It focuses on product innovation, production, and medical education for orthopedics. The combined company's global research, development, commercial and manufacturing footprint includes facilities in Irvine, California; Toronto, Canada; Sunnyvale, California; Maidenhead, UK; Munich, Germany; Paris, France; and São Paulo, Brazil; This includes offices.
Forward-looking statements
This news release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Other words may include “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” and “plan,” as the case may be. You can identify forward-looking statements by terms such as ”, “intends”, “anticipates”, “potential”, “continue” or other similar terminology. Orthofix cautions that statements contained in this news release that are not statements of historical fact are forward-looking statements that are based on the company's current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the statement. Applicable risks and uncertainties include, among other things, the ability of newly launched products to perform as designed and intended and meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and under the heading “Risk Factors” in Orthofix Medical Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on March 5, 2024. Contains identified risks. The company's filings with the Securities and Exchange Commission are available at www.sec.gov. Please do not place undue reliance on forward-looking statements, as they speak only as of the date on which they are made. Orthofix does not intend to revise or update the forward-looking statements contained in this news release to reflect events or circumstances occurring after the date of this news release, except as required by law. there is no.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523192754/ja/
contact address
Media contact point
Dennis Landry
dennis.landry@orthofix.com
214.937.2529
PR for investors
Louisa Smith, Gilmartin Group
IR@orthofix.com
